Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily,
Non-Statin LDL-Cholesterol Lowering MedicineFebruary 21, 2020
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in the U.S. in Nearly 20 Years for Indicated Patients –– NEXLETOL Lowers LDL-Cholesterol with a First-in-Class Mechanism –– Fills an Unmet Need for Affordable Medicines for Millions of Patients with ASCVD or HeFH –– NEXLETOL will be Commercially Available in the U.S. March 30, 2020 –– Conference Call and Webcast on Monday, February 24 at 8:00 a.m. Eastern Time –ANN ARBOR, Mich., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced today that the U.S. Food and Drug
Administration (FDA) approved NEXLETOL™ (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine.
NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial
hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. The effect ofNEXLETOL on cardiovascular morbidity and mortality has not been determined. NEXLETOL is the first oral, once-daily, non-statin LDL-C lowering
medicine approved since 2002 for indicated patients.
NEXLETOL is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by inhibition of cholesterol synthesis in the liver.
“NEXLETOL delivers upon a commitment we’ve made to millions of patients for a new treatment alternative if they struggle with bad cholesterol andhave ASCVD or HeFH,” said Tim Mayleben, president and chief executive officer of Esperion. “Even with maximally tolerated statins, which may mean
no statin at all, some of these patients can’t achieve their LDL-C goals. Today’s approval provides them with a new medicine to go along with a healthy
diet. We express our sincere gratitude to all of the patients and physicians who put their confidence in Esperion’s team of lipid experts.”
LDL-C is a waxy, fat-like substance that’s found in the body. Elevated LDL-C contributes to a buildup of this fat in the arteries and can lead to
cardiovascular events including heart attack and stroke. Despite standard of care treatments, including statin therapy, it is estimated nearly 15 million
patients (approximately one in four patients) in the U.S. cannot achieve guideline recommended LDL-C levels.
“The FDA approval of NEXLETOL provides an important option for patients living with elevated LDL-C and ASCVD or increased risk for cardiovasculardisease because of HeFH,” said Christie M. Ballantyne, M.D., chairman of Esperion’s Phase 3 Executive Committee and professor and chief ofcardiology at Baylor College of Medicine in Houston. “There are millions of patients who are unable to reach their LDL-C targets despite availablemedicines. NEXLETOL is the first oral, once-daily, non-statin treatment option for indicated patients in nearly two decades.”The approval of NEXLETOL is supported by a global pivotal Phase 3 LDL-C lowering program conducted in more than 3,000 patients. In thesestudies, NEXLETOL provided an average of 18 percent placebo corrected LDL-C lowering when used with moderate or high intensity statins. Resultsfrom the Phase 3 development program have been published in The New England Journal of Medicine (040 Study), and The Journal of the American
Medical Association (047 Study).
NEXLETOL was generally well-tolerated in clinical studies. Label warnings and precautions include hyperuricemia, with the development of gout in asmall percentage of patients, as well as increased risk of tendon rupture or injury. Overall in Phase 3 studies, the adverse events reported mostfrequently in patients who received NEXLETOL were generally reported at similar rates in patients who received placebo. The most common adverseevents reported with NEXLETOL (incidence ≥ 2% and greater than placebo) were upper respiratory tract infections, muscle spasms, hyperuricemia,back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, and elevated liver enzymes. The majority of adverse events reportedwith NEXLETOL were mild to moderate in severity and balanced in occurrence with adverse events in patients receiving placebo. For additional
information on NEXLETOL, please see Full Prescribing Information at Esperion.com.
Today’s approval underscores Esperion’s commitment to deliver NEXLETOL to adult patients suffering from ASCVD or HeFH and who are unable toreach their LDL-C goal on maximally tolerated statins. Esperion is working with health insurance providers to help ensure broad insurance coverageand patient access to NEXLETOL. Eligible patients with commercial drug insurance coverage for NEXLETOL may pay as little as $10 per fill, up to a3-month supply. Additionally, Esperion is committed to achieving the lowest branded tier coverage for Medicare patients. Esperion will provideresources to patients whose physician recommends treatment with NEXLETOL. These resources include educational materials, a dedicated callcenter, as well as a co-pay program for eligible patients.
NEXLETOL will be commercially available in the U.S., by prescription only, on March 30, 2020.
Esperion’s second LDL-C lowering medicine, the bempedoic acid / ezetimibe combination tablet, is currently under review by the U.S. FDA; thePDUFA goal date is February 26, 2020.
Conference Call and Webcast Information
Esperion's Lipid Management Team will host a conference call and webcast on Monday, February 24 at 8:00 a.m. Eastern Time to discuss theapproval and upcoming commercial launch. The call can be accessed by dialing (877) 312-7508 (domestic) or (253) 237-1184 (international) fiveminutes prior to the start of the call and providing the access code 4088218. A live audio webcast can be accessed on the investors and media sectionof the Esperion website at investor.esperion.com. Access to the webcast replay will be available approximately two hours after completion of the calland will be archived on the Company's website for approximately 90 days.
NEXLETOLTM (bempedoic acid) Tablet

NEXLETOL is a first-in-class ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C by reducing cholesterol biosynthesis and up-regulating the LDLreceptors. Completed Phase 3 studies conducted in more than 3,000 patients, with over 2,000 patients treated with NEXLETOL, demonstrated anaverage 18 percent placebo corrected LDL-C lowering when used in patients on moderate or high-intensity statins. NEXLETOL is the first oral,
once-daily, non-statin LDL-C lowering medicine approved in the U.S. in nearly 20 years for patients with ASCVD or HeFH. NEXLETOL was approvedby the FDA in February 2020.
Indication and Limitation of Use
NEXLETOL is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial
hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The effect of NEXLETOL on
cardiovascular morbidity and mortality has not been determined.
Important Safety Information

Warnings and Precautions:Elevations in serum uric acid have occurred. Assess uric acid levels periodically as clinically indicated. Monitor forsigns and symptoms of hyperuricemia, and initiate treatment with urate-lowering drugs as appropriate. The risk forgout events with NEXLETOL was higher in patients with a prior history of gout although gout also occurred more
frequently than placebo in patients treated with NEXLETOL who had no prior gout history.
Tendon rupture has occurred. Discontinue NEXLETOL at the first sign of tendon rupture. Avoid NEXLETOL inpatients who have a history of tendon disorders or tendon rupture.
Adverse Reactions:
The most common (incidence ≥ 2% and greater than placebo) adverse reactions are upper respiratory tract
infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity,
anemia and elevated liver enzymes.
Drug Interactions:
Avoid concomitant use of NEXLETOL with simvastatin greater than 20 mg.
Avoid concomitant use of NEXLETOL with pravastatin greater than 40 mg.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088 or reportside effects to Esperion at 833-377-7633 (833 ESPRMED).
CLEAR Cardiovascular Outcomes Trial
The effect of NEXLETOL on cardiovascular morbidity and mortality has not been determined. Esperion initiated a global cardiovascular outcomes trial(CVOT) to assess the effects of NEXLETOL on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovasculardisease (CVD) who are only able to tolerate less than the lowest approved daily starting dose of a statin and are considered "statin averse." The CVOT— known as CLEAR Cardiovascular Outcomes Trial — is an event-driven, global, randomized, double-blind, placebo-controlled study that completed
enrollment in August 2019 of 14,032 patients with hypercholesterolemia and high CVD risk at over 1,400 sites in 32 countries.
Esperion Therapeutics
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion iscommitted to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading
cause of death around the world. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc
Esperion Therapeutics’ Commitment to Patients with Hyperlipidemia
High levels of LDL-C can lead to a build-up of fat and cholesterol in and on artery walls (known as atherosclerosis), potentially leading tocardiovascular events, including heart attack or stroke. In the U.S., 96 million people, or more than 37 percent of the adult population, have elevated
LDL-C. There are approximately 18 million people in the U.S. with atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial
hypercholesterolemia (HeFH) living with elevated levels of LDL-C despite taking maximally tolerated lipid-modifying therapy — including individuals
considered statin averse — leaving them at high risk for cardiovascular events1. In the United States, more than 50 percent of ASCVD patients who
are not able to reach their LDL-C with statins alone need less than a 40 percent reduction to reach their LDL-C threshold2.
Esperion's mission as the Lipid Management Company is to deliver oral, once-daily medicines that complement existing oral drugs to provide theadditional LDL-C lowering that these patients need.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including
statements regarding the regulatory approval pathway for bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, thetherapeutic potential of, and the clinical development plan for bempedoic acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet,
including Esperion's timing, designs, plans for announcement of results regarding its CLEAR Outcomes study and other ongoing clinical studies forbempedoic acid tablet and the bempedoic acid / ezetimibe combination fixed dose tablet, timing for the review and approval of the NDAs and theMAAs, and Esperion's expectations for the market for medicines to lower LDL-C, including the commercial launch and market adoption of bempedoic
acid tablet and the bempedoic acid / ezetimibe fixed dose combination tablet, if approved. Any express or implied statements contained in this press
release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks anduncertainties that could cause Esperion's actual results to differ significantly from those projected, including, without limitation, delays or failures in
Esperion’s studies, that positive results from a clinical study of bempedoic acid may not be sufficient for EMA approval or necessarily be predictive of
the results of future or ongoing clinical studies, that notwithstanding the completion of Esperion’s Phase 3 clinical development program for LDL-Clowering, the FDA or EMA require additional development in connection with seeking regulatory approval, or approval of an expanded indication, that

existing cash resources may be used more quickly than anticipated, and the risks detailed in Esperion's filings with the Securities and Exchange
Commission. Esperion disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release,other than to the extent required by law.
References(1) Esperion market research on file: research project interviewing 350 physicians. Esperion Therapeutics, Inc. Sept-Oct 2018.
(2) Data on file: analysis of NHANES database. Esperion Therapeutics, Inc. 2018.

Investor Contact:
Alex Schwartz
Esperion734-249-3386
aschwartz@esperion.com
Media Contact:
Ben Church
Esperion
734-864-6774
bchurch@esperion.com
Media Contact:
Elliot Fox
W2Opure212-257-6724
efox@purecommunications.com